Abstract
There are many factors that can play a role in the susceptibility of infection to lumpy skin disease virus (LSDV). The interaction between the host’s immune system and the virus determines the outcome. Following natural or experimental infection of cattle with virulent LSDV, virus neutralizing antibodies are elicited. These antibodies are detected starting around 15 days following infection, with the titres of the antibodies increasing over the next 2 weeks and then wane. With capripoxvirus infections, mild infections generate lower antibody responses compared to severe infections (Bowden et al. 2009). Unfortunately, following vaccination with several of the currently available vaccines, in many times only low or undetectable levels of virus neutralizing antibodies are elicited.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Amara RR, Nigam P, Sharma S, Liu J, Bostik V (2004) Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78:3811–3816
Bowden TR, Coupar BE, Babiuk SL, White JR, Boyd V, Duch CJ, Shiell BJ, Ueda N, Parkyn GR, Copps JS, Boyle DB (2009) Detection of antibodies specific for sheeppox and goatpox viruses using recombinant capripoxvirus antigens in an indirect enzyme-linked immunosorbent assay. J Virol Methods 161:19–29
Bray M, Wright ME (2003) Progressive vaccinia. Clin Infect Dis 36:766–774
Chaudhri G, Panchanathan V, Bluethmann H, Karupiah G (2006) Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 80:6339–6344
Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R (2003) Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171:4969–4973
Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11:740–747
Galmiche MC, Goenaga J, Wittek R, Rindisbacher L (1999) Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254:71–80
Gilchuk P, Spencer CT, Conant SB, Hill T, Gray JJ, Niu X, Zheng M, Erickson JJ, Boyd KL, McAfee KJ, Oseroff C, Hadrup SR, Bennink JR, Hildebrand W, Edwards KM, Crowe JE Jr, Williams JV, Buus S, Sette A, Schumacher TN, Link AJ, Joyce S (2013) Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest 123:1976–1987
Gordon J, Mohandas A, Wilton S, Dales S (1991) A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope. Virology 181:671–686
Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9:1131–1137
Hathaway WE, Githens JH, Blackburn WR, Fulginiti V, Kempe CH (1965) Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children: probable human runt disease. N Engl J Med 273:953–958
Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G (2006) Subunit recombinant vaccine protects against monkeypox. J Immunol 177:2552–2564
Hooper JW, Custer DM, Thompson E (2003) Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181–195
Hsiao JC, Chung CS, Chang W (1999) Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 73:8750–8761
Kitching RP (1986) Passive protection of sheep against capripoxvirus. Res Vet Sci 41:247–250
Moise L, McMurry JA, Buus S, Frey S, Martin WD, De Groot AS (2009) In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 27:6471–6479
Moutaftsi M, Tscharke DC, Vaughan K, Koelle DM, Stern L, Calvo-Calle M, Ennis F, Terajima M, Sutter G, Crotty S, Drexler I, Franchini G, Yewdell JW, Head SR, Blum J, Peters B, Sette A (2010) Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol 5:221–239
Ngichabe CK, Wamwayi HM, Ndungu EK, Mirangi PK, Bostock CJ, Black DN, Barrett T (2002) Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiol Infect 128:343–349
Panchanathan V, Chaudhri G, Karupiah G (2006) Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol 80:6333–6338
Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM (2007) Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 81:4070–4079
Perrin LH, Zinkernagel RM, Oldstone MB (1977) Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes. J Exp Med 146:949–969
Rodriguez JF, Janeczko R, Esteban M (1985) Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol 56:482–488
Sette A, Grey H, Oseroff C, Peters B, Moutaftsi M, Crotty S, Assarsson E, Greenbaum J, Kim Y, Kolla R, Tscharke D, Koelle D, Johnson RP, Blum J, Head S, Sidney J (2009) Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 27(Suppl 6):G21–G26
Weiss KE (1968) Lumpy skin disease virus. Virol Monogr 3:111–131
Wolffe EJ, Vijaya S, Moss B (1995) A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211:53–63
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Babiuk, S. (2018). Immunity. In: Lumpy Skin Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-92411-3_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-92411-3_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92410-6
Online ISBN: 978-3-319-92411-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)